Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Angiogenesis
Published in: Angiogenesis 1/2011

01-03-2011 | Original Paper

RETRACTED ARTICLE: Gold nanoparticles inhibit vascular endothelial growth factor-induced angiogenesis and vascular permeability via Src dependent pathway in retinal endothelial cells

Authors: Kalimuthu Kalishwaralal, Sardarpasha Sheikpranbabu, Selvaraj BarathManiKanth, Ravinarayanan Haribalaganesh, Sureshbabu Ramkumarpandian, Sangiliyandi Gurunathan

Published in: Angiogenesis | Issue 1/2011

Login to get access

Abstract

The purpose of this study was to investigate the effect of gold nanoparticles on the signaling cascade related to angiogenesis and vascular permeability induced by Vascular Endothelial Growth Factor (VEGF) in Bovine retinal endothelial cells (BRECs). The effect of VEGF and gold nanoparticles on cell viability, migration and tubule formation was assessed. PP2 (Src Tyrosine Kinase inhibitor) was used as the positive control and the inhibitor assay was performed to compare the effect of AuNPs on VEGF induced angiogenesis. The transient transfection assay was performed to study the VEGFR2/Src activity during experimental conditions and was confirmed using western blot analysis. Treatment of BRECs with VEGF significantly increased the cell proliferation, migration and tube formation. Furthermore, gold nanoparticles (500 nM) significantly inhibited the proliferation, migration and tube formation, in the presence of VEGF in BRECs. The gold nanoparticles also inhibited VEGF induced Src phosphorylation through which their mode of action in inhibiting angiogenic pathways is revealed. The fate of the gold nanoparticles within the cells is being analyzed using the TEM images obtained. The potential of AuNPs to inhibit the VEGF165-induced VEGFR-2 phosphorylation is also being confirmed through the receptor assay which elucidates one of the possible mechanism by which AuNPs inhibit VEGF induced angiogenesis. These results indicate that gold nanoparticles can block VEGF activation of important signaling pathways, specifically Src in BRECs and hence modulation of these pathways may contribute to gold nanoparticles ability to block VEGF-induced retinal neovascularization.
Literature
1.
Carmeliet P (2000) VEGF gene therapy: stimulating angiogenesis or angioma-genesis? Nat Med 6:1102–1103PubMedCrossRef
2.
Cross MJ, Claesson-Welsh L (2001) FGF and VEGF function in angiogenesis: signaling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 22:201–207PubMedCrossRef
3.
Aiello LP, Avery RL, Arrigg PG, Bruce AK, Henry DJ, Sabera TS (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480–1487PubMedCrossRef
4.
Hata Y, Nakagawa K, Ishibashi T, Inomata H, Ueno H, Sueishi K (1995) Hypoxia-induced expression of vascular endothelial growth factor by retinal glial cells promotes in vitro angiogenesis. Virchows Arch 426:479–486PubMedCrossRef
5.
6.
Ferrara N, Davis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18:4–25PubMedCrossRef
7.
Millauer B, Wizigmann-Voos S, Schnurch H, Martinez R, Moller NP, Risau W (1993) High-affinity VEGF binding and developmental expression suggests Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72:835–846PubMedCrossRef
8.
Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML (1995) Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376:62–66PubMedCrossRef
9.
Shen BQ, Lee DY, Zioncheck TF (1999) Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway. J Biol Chem 274:33057–33063PubMedCrossRef
10.
Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN (2006) Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 142:1–9PubMedCrossRef
11.
Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR (2004) VEGF inhibition study in ocular neovascularization clinical trial group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351:2805–2816PubMedCrossRef
12.
Economopoulou M, Bdeir K, Cines DB, Franz F, Yasmina B (2005) Inhibition of pathologic retinal neovascularization by alpha-defensins. Blood 106:3831–3838PubMedCrossRef
13.
Konopatskaya O, Churchill AJ, Harper SJ, Bates DO, Gardiner TA (2006) VEGF165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularization in mice. Mol Vis 12:626–632PubMed
14.
Ojima T, Takagi H, Suzuma K, Oh H, Suzuma I, Ohashi H (2006) Ephrin A1 inhibits vascular endothelial growth factor-induced intracellular signaling and suppresses retinal neovascularization and blood-retinal barrier breakdown. Am J Pathol 168:331–339PubMedCrossRef
15.
Shen J, Yang X, Xiao WH, Hackett SF, Sato Y, Campochiaro PA (2006) Vasohibin is up-regulated by VEGF in the retina and suppresses VEGF receptor 2 and retinal neovascularization. FASEB J 20:723–725PubMed
16.
Xia X, Xiong S, Song W, Luo J, Wang Y, Zhou R (2008) Inhibition of retinal neovascularization by siRNA targeting VEGF165. Mol Vis 14:1965–1973PubMed
17.
Ghosh P, Han G, Mrinmoy De, Kim CK, Rotello VM (2008) Gold nanoparticles in delivery applications. Adv Drug Deliv Rev 60:1307–1315PubMedCrossRef
18.
Paciotti GF, Myer L, Weinreich D, Goia D, Pavel N, McLaughlin RE, Tamarkin L (2004) Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. Drug Deliv 11:169–183PubMedCrossRef
19.
Davda J, Labhasetwar V (2002) Characterization of nanoparticle uptake by endothelial cells. Int J Pharm 233:51–59PubMedCrossRef
20.
Kalishwaralal K, Banumathi E, Pandian SRK, Deepak V, Muniyandi J, Eom SH, Gurunathan S (2009) Silver nanoparticles inhibit VEGF-induced cell proliferation and migration in bovine retinal endothelial cells. Colloid Surf B 73:51–57CrossRef
21.
Kalimuthu K, Babu RS, Venkataraman D, Bilal M, Gurunathan S (2008) Biosynthesis of silver nanocrystals by Bacillus licheniformis. Colloids Surf B 65:150–153CrossRef
22.
Kalishwaralal K, Deepak V, Ram Kumar Pandian S, Gurunathan S (2009) Biological synthesis of gold nanocubes from Bacillus licheniformis. Bioresour Technol 100:5356–5358PubMedCrossRef
23.
Liu X, Atwater M, Wang J, Huo Q (2007) Extinction coefficient of gold nanoparticles with different sizes and different capping ligands. Colloids Surf B 58:3–7CrossRef
24.
Banumathi E, Haribalaganesh R, Babu SSP, Kumar NS, Sangiliyandi G (2009) High-yielding enzymatic method for isolation and culture of microvascular endothelial cells from bovine retinal blood vessels. Microvasc Res 77:377–381PubMedCrossRef
25.
Gurunathan S, Lee KJ, Kalishwaralal K, Sheikpranbabu S, Vaidyanathan R, Eom SH (2009) Antiangiogenic properties of silver nanoparticles. Biomaterials 31:6341–6350CrossRef
26.
Sheikpranbabu S, Kalishwaralal K, Venkataraman D, Eom SH, Park J, Gurunathan S (2009) Silver nanoparticles inhibit VEGF-and IL-1β-induced vascular permeability via Src dependent pathway in porcine retinal endothelial cells. J Nanobiotechnol 7:8CrossRef
27.
Kumar SA, Peter YA, Nadeau JL (2008) Facile biosynthesis, separation and conjugation of gold nanoparticles to doxorubicin. Nanotechnology 19:495101PubMedCrossRef
28.
Sastry M, Patil V, Sainkar SRJ (1998) Electrostatically controlled diffusion of carboxylic acid derivatized silver colloidal particles in thermally evaporated fatty amine films. Phys Chem B 102:1404–1410CrossRef
29.
Eliceiri BP, Paul R, Schwartzberg PL, Hood JD, Leng J, Cheresh DA et al (1999) Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell 4:915–924PubMedCrossRef
30.
Liu F, Verin AD, Wang P, Day R, Wersto RP, Chrest FJ et al (2001) Differential regulation of sphingosine-1-phosphate and VEGF-induced endothelial cell chemotaxis: involvement of G (ialpha2)-linked Rho kinase activity. Am J Respir Cell Mol Biol 24:711–719PubMed
31.
Paul R, Zhang ZG, Eliceiri BP, Jiang Q, Boccia AD, Zhang RL (2001) Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke. Nat Med 7:222–227PubMedCrossRef
32.
33.
Harhaj NS, Antonetti DA (2004) Regulation of tight junctions and loss of barrier function in pathophysiology. Int J Biochem Cell Biol 36:1206–1237PubMedCrossRef
34.
Parsons JT, Parsons SJ (1997) Src family protein tyrosine kinases: cooperating with growth factor and adhesion signaling pathways. Curr Opin Cell Biol 9:187–192PubMedCrossRef
35.
Mukherjee P, Bhattacharya R, Wang P, Wang L, Basu S, Nagy JA (2005) Antiangiogenic properties of gold nanoparticles. Clin Cancer Res 11:3530–3534PubMedCrossRef
36.
Murugesan S, Mousa SA, O’Connor LJ, Lincoln DW II, Linhardt RJ (2007) Carbon inhibits vascular endothelial growth factor- and fibroblast growth factor promoted angiogenesis. FEBS Lett 581:1157–1160PubMedCrossRef
37.
Nakashio A, Fujita N, Tsuruo T (2002) Topotecan inhibits VEGF- and bFGF-induced vascular endothelial cell migration via downregulation of the PI3 K-Akt signaling pathway. Int J Cancer 98:36–41PubMedCrossRef
38.
Favot L, Keravis T, Holl V, Le Bec A, Lugnier C (2003) VEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors. Thromb Haemost 90:334–343PubMed
39.
Thomas SM, Brugge JS (1997) Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 13:513–609PubMedCrossRef
40.
Nam JS, Ino Y, Sakamoto M, Hirohashi S (2002) Src family kinase inhibitor PP2 restores the E cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis. Clin Cancer Res 8:2430–2436PubMed
41.
Boyer B, Bourgeois Y, Poupon MF (2002) Src kinase contributes to the metastatic spread of carcinoma cells. Oncogene 21:2347–2356PubMedCrossRef
42.
Thurston G, Suri C, Smith K, McClain J, Sato TN, Yancopoulos GD, McDonald DM (1999) Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 286:2511–2514PubMedCrossRef
43.
He H, Venema VJ, Gu X, Venema RC, Marrero MB, Caldwell RB (1999) Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src. J Biol Chem 274:25130–25135PubMedCrossRef
44.
Irby RB, Mao W, Coppola D, Kang J, Loubeau JM, Trudeau W (1999) Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet 21:187–190PubMedCrossRef
45.
Simeonova PP, Wang S, Hulderman T, Luster MI (2002) c-Src-dependent activation of the epidermal growth factor receptor and mitogen-activated protein kinase pathway by arsenic: role in carcinogenesis. J Biol Chem 277:2945–2950PubMedCrossRef
46.
Brown MT, Cooper JA (1996) Regulation, substrates and functions of src. Biochi Biophys Acta 1287:121–149
47.
Abram CL, Courtneidge SA (2000) Src family tyrosine kinases and growth factor signaling. Exp Cell Res 254:1–13PubMedCrossRef
48.
Priyabrata M, Resham B, Nancy B, Yean KL, Chitta Ranjan P, Shanfeng W, Lichun L, Charla S, Pataki CB, Michael JY, Neil EK (2007) Potential therapeutic application of gold nanoparticles in B-chronic lymphocytic leukemia (BCLL): enhancing apoptosis. J Nanobiotechnol 5:4CrossRef
Metadata
Title
RETRACTED ARTICLE: Gold nanoparticles inhibit vascular endothelial growth factor-induced angiogenesis and vascular permeability via Src dependent pathway in retinal endothelial cells
Authors
Kalimuthu Kalishwaralal
Sardarpasha Sheikpranbabu
Selvaraj BarathManiKanth
Ravinarayanan Haribalaganesh
Sureshbabu Ramkumarpandian
Sangiliyandi Gurunathan
Publication date
01-03-2011
Publisher
Springer Netherlands
Published in
Angiogenesis / Issue 1/2011
Print ISSN: 0969-6970
Electronic ISSN: 1573-7209
DOI
https://doi.org/10.1007/s10456-010-9193-x

Other articles of this Issue 1/2011

Angiogenesis 1/2011 Go to the issue

Original Paper

SR16388: a steroidal antiangiogenic agent with potent inhibitory effect on tumor growth in vivo

Abstract

Meeting abstracts of the 4th international meeting on angiogenesis

Original Paper

Mesenchymal stem cells from adipose and bone marrow promote angiogenesis via distinct cytokine and protease expression mechanisms

Original Paper

Treprostinil increases the number and angiogenic potential of endothelial progenitor cells in children with pulmonary hypertension

Original Paper

Vascular endothelial growth inhibitor (VEGI; TNFSF15) inhibits bone marrow-derived endothelial progenitor cell incorporation into Lewis lung carcinoma tumors
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits